Prolifica is a 5 year European Commision (EC) funded medical research programme to look at the link between viral hepatitis and liver cancer

Objectives:

Understanding the Link:

Investigate how viral hepatitis contributes to the development of liver cancer.

Identify key mechanisms and pathways involved in the progression from hepatitis to cancer.

Epidemiological Studies:

Conduct large-scale studies to assess the prevalence and impact of viral hepatitis in different populations.

Analyze data to identify high-risk groups and geographic areas with higher incidences of liver cancer.

Improving Diagnostics:

Develop and refine diagnostic tools for early detection of viral hepatitis and liver cancer.

Enhance screening programs to identify affected individuals sooner, improving treatment outcomes.

Treatment and Prevention:

Explore new therapeutic approaches and preventive measures for viral hepatitis and liver cancer.

Test the efficacy of existing treatments and develop guidelines for best practices in management.

Public Health Impact:

Assess the broader impact of viral hepatitis on public health and healthcare systems.

Promote awareness and education on the risks of viral hepatitis and its link to liver cancer.

Key Activities:

Research Collaboration: Bringing together researchers, healthcare professionals, and institutions across Europe to collaborate on studies and share findings.

Clinical Trials: Conducting clinical trials to test new treatments and interventions for viral hepatitis and liver cancer.

Data Collection and Analysis: Gathering comprehensive data on viral hepatitis and liver cancer cases to inform research and policy decisions.

Education and Outreach: Engaging with the public and healthcare providers to disseminate knowledge and promote preventive measures.

Simplifying the cancer treatment process

We provide tailored advice and support to help you through your cancer journey.

Hepatitis B (HBV) is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem and the most serious type of viral hepatitis. It can cause chronic liver disease and puts people at high risk of death from cirrhosis of the liver and liver cancer.

Prolifica is a 5 year European Commision (EC) funded medical research programme to look at the link between viral hepatitis and liver cancer

Objectives:

Key Activities:

Simplifying the cancer treatment process

Our team involves leading scientists in translational and clinical ﬁelds of cancer and disease from 6 different countries.

The aim of the study is to reduce the risk of liver cancer in Africa by the suppression of Hepatitis B infection